Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIBEX Technologies Inc

IBEX Technologies Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.44 CAD 0.00(0%)
Last update at 2024-04-10T13:30:00Z
Market Cap
26.23M
P/E
7.13

Momentum Score

…

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.44
Low
1.44
High
52 Week Price Range
0.74
Low
1.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
1.44
Dividend Yield
-
Revenue TTM
7.80M
Revenue Per Share
0.30
Gross Profit TTM
5.36M
Debt / Equity
-
ROE
32.57%
Net Debt
-
ROCE
12.29%
Diluted EPS TTM
0.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Income before tax 2.02M 2.39M 0.97M 1.28M -1.33M
Net income 3.89M 1.67M 0.76M 0.97M -1.27M
Selling general administrative 3.05M 2.74M 2.04M 2.10M 2.09M
Gross profit 5.20M 5.36M 3.03M 2.97M 1.36M
Reconciled depreciation 0.44M 0.37M 0.39M 0.17M 0.28M
Ebit - 2.27M 0.86M 0.74M -1.03M
Ebitda - 2.83M 1.40M 1.54M -0.98M
Operating income 1.85M 2.27M 0.86M 0.87M -1.03M
Interest expense 0.10M 0.08M 0.05M 0.08M 0.06M
Tax provision -1.88M 0.71M 0.20M 0.32M -0.06M
Interest income 0.36M 0.05M 0.01M 0.03M 0.05M
Net interest income 0.26M -0.03M -0.04M -0.05M -0.02M
Income tax expense - 0.71M 0.20M 0.32M -0.06M
Total revenue 7.49M 7.89M 5.31M 5.21M 4.31M
Total operating expenses 5.64M 5.62M 4.45M 4.34M 5.34M
Cost of revenue 2.29M 2.53M 2.27M 2.24M 2.95M
Total other income expense net -0.09M 0.15M 0.15M 0.47M -0.28M
Net income from continuing ops 3.89M 1.67M 0.76M 0.97M -1.27M
Net income applicable to common shares - 1.67M 0.76M 0.97M -1.27M
Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Total assets 16.83M 12.97M 9.46M 8.59M 8.39M
Intangible assets 0.04M - 0.00M 0.01M 0.02M
Other current assets - - - 0.13M -
Total liab 3.22M 3.23M 1.56M 1.47M 1.81M
Total stockholder equity 13.61M 9.75M 7.90M 7.12M 6.57M
Common stock - 52.68M 52.68M 52.67M 52.67M
Capital stock 52.54M 52.68M 52.68M 52.67M 52.67M
Retained earnings -40.02M -43.91M -45.59M -46.35M -47.31M
Other assets - 1.25M 1.92M 2.13M 2.44M
Cash 8.55M 7.64M 4.43M 3.71M 2.58M
Total current liabilities 1.80M 1.75M 1.10M 1.11M 0.88M
Short term debt - - - - 0.06M
Short long term debt - - - - 0.06M
Other stockholder equity - - - - 0.50M
Property plant equipment - 2.67M 2.34M 1.54M 2.21M
Total current assets 10.23M 9.03M 5.83M 4.91M 3.71M
Net tangible assets - 9.75M 7.90M 7.11M 6.55M
Net receivables 0.90M 0.99M 0.95M 0.75M 0.90M
Long term debt - - - - 0.94M
Inventory 0.17M 0.23M 0.32M 0.23M 0.15M
Accounts payable 1.59M 1.58M 0.94M 0.94M 0.82M
Non currrent assets other - - - - 4.67M
Non current assets total 6.60M 3.92M 3.63M 3.68M 4.67M
Capital lease obligations 1.64M 1.62M 0.62M 0.53M -
Breakdown 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Type yearly yearly yearly yearly yearly
Date 2023-07-31 2022-07-31 2021-07-31 2020-07-31 2019-07-31
Investments -1.01M -0.14M -0.27M 0.95M -0.05M
Change to liabilities - 0.63M -0.00M 0.12M 0.20M
Total cashflows from investing activities - -0.14M -0.27M 0.95M -0.05M
Net borrowings - -0.23M -0.21M -1.20M -0.05M
Total cash from financing activities -0.33M -0.23M -0.21M -1.20M -0.05M
Change to operating activities - -0.04M -0.02M -0.02M 0.00M
Net income 3.89M 1.67M 0.76M 0.97M -1.27M
Change in cash 0.91M 3.21M 0.73M 1.13M -0.56M
Begin period cash flow 7.64M 4.43M 3.71M 2.58M 3.14M
End period cash flow 8.55M 7.64M 4.43M 3.71M 2.58M
Total cash from operating activities 2.25M 3.58M 1.21M 1.37M -0.45M
Depreciation 0.44M 0.37M 0.38M 0.39M 0.27M
Change to inventory 0.06M 0.09M -0.09M -0.09M 0.20M
Change to account receivables - -0.04M -0.08M 0.03M -0.19M
Sale purchase of stock -0.04M - - - -
Change to netincome - 0.89M 0.25M -0.04M 0.32M
Capital expenditures 1.01M 0.14M 0.27M 0.10M 0.07M
Change in working capital -0.29M 0.65M -0.19M 0.04M 0.21M
Stock based compensation 0.01M 0.17M 0.02M 0.08M 0.04M
Other non cash items 0.07M 0.05M 0.03M -0.47M -
Free cash flow 1.24M 3.44M 0.94M 1.27M -0.52M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IBT
IBEX Technologies Inc		 -
-%		 1.44 7.13 - 3.36 1.83 2.45 7.03
SHRX
Sharp Therapeutics Corp.		 -
-%		 1.37 - - - 32.37 - -
NRX
NurExone Biologic Inc.		 -0.03
5.00%		 0.47 - 6.90 - 15.26 - -7.24
MIR
MedMira Inc		 -0.01
9.09%		 0.05 - - 223.37 - 293.42 -80.03
TTI
Thiogenesis Therapeutics Corp.		 -
-%		 0.63 - - - 15.17 - -58.16

Profile*

IBEX Technologies Inc

IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.

5485 Rue Pare, Montreal, QC, Canada, H4P 1P7

514 344 4004

https://www.ibex.ca

Name Title Year Born
Mr. Paul Baehr Pres, CEO & Chairman 1943
Belinda Franco C.A., CPA CFO, VP of Fin. & Admin. and Sec. NA
Mahendra Kumar Pallapothu VP of Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.34
+14.45%
OMG
CAD 1.70
+13.76%
ARTG
CAD 39.54
+12.59%
DSV
CAD 10.83
+12.58%
TLRY
CAD 4.17
+12.10%
DRUG
CAD 25.95
-30.02%
HUT
CAD 69.16
-22.20%
UCU
CAD 2.04
-16.39%
PHX
CAD 10.70
-15.62%
VET
CAD 15.04
-13.31%

Equity Sectors*

  • Basic Materials

    +4.80%

  • Communication Services

    +2.78%

  • Consumer Cyclical

    +2.82%

  • Consumer Defensive

    +0.74%

  • Energy

    -4.92%

  • Financial Services

    +2.47%

  • Healthcare

    -0.30%

  • Industrials

    -0.38%

  • Real Estate

    +1.75%

  • Technology

    +0.82%

  • Utilities

    +1.29%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…